2002
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2])
Kuntz RE, Baim DS, Cohen DJ, Popma JJ, Carrozza JP, Sharma S, McCormick DJ, Schmidt DA, Lansky AJ, Ho KK, Dandreo KJ, Setum CM, Ramee SR, Investigators V. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). The American Journal Of Cardiology 2002, 89: 326-330. PMID: 11809436, DOI: 10.1016/s0002-9149(01)02235-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary ThrombosisDisease-Free SurvivalFemaleFibrinolytic AgentsGraft Occlusion, VascularHemorheologyHumansInfusions, Intra-ArterialMaleMiddle AgedThrombectomyTreatment OutcomeUnited StatesUrokinase-Type Plasminogen Activator
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose